The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Tampilan
administrator
07/18/23
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
Menampilkan lebih banyak
Komentar Facebook
![Actinic Keratosis Treatment and Cancer Potential - Eyelid, Face, and Neck [Dermatology Course 32/60]](https://i.ytimg.com/vi/ffcHWDpKZqQ/maxresdefault.jpg)
Tidak ada komentar yang ditemukan